Results 281 to 290 of about 420,896 (315)
Some of the next articles are maybe not open access.
Archives of Internal Medicine, 1976
The difference between the chemotherapeutic response in patients with acute myelocytic leukemia (AML) and in those with acute lymphocytic leukemia (ALL) would appear to be more a problem of lack of regeneration of normal myeloid tissues than a lack of susceptibility of the neoplastic cell to chemotherapy.
Wallace Hj +10 more
openaire +3 more sources
The difference between the chemotherapeutic response in patients with acute myelocytic leukemia (AML) and in those with acute lymphocytic leukemia (ALL) would appear to be more a problem of lack of regeneration of normal myeloid tissues than a lack of susceptibility of the neoplastic cell to chemotherapy.
Wallace Hj +10 more
openaire +3 more sources
Clinics in Geriatric Medicine, 1997
More elderly persons than children will develop acute leukemia this year in the United States. Several recent studies have been conducted on acute myeloid leukemia in the elderly, and some therapeutic clues have emerged. Far fewer data are available on acute lymphocytic leukemia. Quality of life studies are producing their first results.
openaire +3 more sources
More elderly persons than children will develop acute leukemia this year in the United States. Several recent studies have been conducted on acute myeloid leukemia in the elderly, and some therapeutic clues have emerged. Far fewer data are available on acute lymphocytic leukemia. Quality of life studies are producing their first results.
openaire +3 more sources
Journal of the American Pharmaceutical Association (1961), 1972
Douglas G. Christian +2 more
openaire +3 more sources
Douglas G. Christian +2 more
openaire +3 more sources
Pediatric Annals, 1983
During the past decade progress in the treatment of childhood acute lymphoblastic leukemia has slowed. A 50% to 60% cure barrier has frustrated a multitudinous array of therapeutic attempts to overcome this obstacle. With few exceptions, intensifications of induction, consolidation, or maintenance therapies have not overcome this obstacle.
openaire +2 more sources
During the past decade progress in the treatment of childhood acute lymphoblastic leukemia has slowed. A 50% to 60% cure barrier has frustrated a multitudinous array of therapeutic attempts to overcome this obstacle. With few exceptions, intensifications of induction, consolidation, or maintenance therapies have not overcome this obstacle.
openaire +2 more sources
1985
Acute leukemias are malignant disorders of blood cells and their precursors characterized by accumulation of primitive cells that are not completely mature in the bone marrow and peripheral blood. These diseases are divided into two groups: acute myelogenous leukemia (AML), derived from myeloid precursors (granulocytes, monocytes, erythroid cells, and ...
openaire +2 more sources
Acute leukemias are malignant disorders of blood cells and their precursors characterized by accumulation of primitive cells that are not completely mature in the bone marrow and peripheral blood. These diseases are divided into two groups: acute myelogenous leukemia (AML), derived from myeloid precursors (granulocytes, monocytes, erythroid cells, and ...
openaire +2 more sources
Current Problems in Cancer, 1997
Untreated acute leukemia is a uniformly fatal disease with a median survival time shorter than 3 months. Current treatment strategies provide a significant increase in survival time for most patients, some of whom may be cured. The majority of patients with acute leukemia, however, ultimately die of the disease or complications of treatment.
openaire +3 more sources
Untreated acute leukemia is a uniformly fatal disease with a median survival time shorter than 3 months. Current treatment strategies provide a significant increase in survival time for most patients, some of whom may be cured. The majority of patients with acute leukemia, however, ultimately die of the disease or complications of treatment.
openaire +3 more sources
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly
New England Journal of Medicine, 1999
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources